Optimalization of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A-677C alleles on probability to respond

Ann Rheum Dis. 2009 Aug;68(8):1371. doi: 10.1136/ard.2008.096891.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Haplotypes / genetics*
  • Humans
  • Methotrexate / therapeutic use*
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics*
  • Models, Genetic*
  • Polymorphism, Single Nucleotide
  • Prognosis
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Methylenetetrahydrofolate Reductase (NADPH2)
  • Methotrexate